WEKO3
アイテム
Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model
https://repo.qst.go.jp/records/49141
https://repo.qst.go.jp/records/4914128d4bd11-c7e1-4def-8e08-35a9082a87e3
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-08-16 | |||||
| タイトル | ||||||
| タイトル | Antitumor effects of radionuclide treatment using α-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
大島, 康宏
× 大島, 康宏× 須藤, 仁美× 渡辺, 茂樹× 永津, 弘太郎× 辻, 厚至× 坂下, 哲哉× 伊藤, 陽一× 吉永, 恵一郎× 東, 達也× 石岡, 典子× 大島 康宏× 須藤 仁美× 渡辺 茂樹× 永津 弘太郎× 辻 厚至× 坂下 哲哉× 吉永 恵一郎× 東 達也× 石岡 典子 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: Therapeutic options for patients with malignant pheochromocytoma are currently limited, and therefore new treatment approaches are being sought. Targeted radionuclide therapy provides tumor-specific systemic treatments. β-emitting radiopharmaceutical meta-131I-iodo-benzylguanidine (131I-MIBG) has limited survival benefits and adverse effects. A new generation of radionuclide therapy using α-particles including meta-211At-astatobenzylguanidine (211At-MABG) is expected to have strong therapeutic effects with minimal side effects. However, this possibility has not been evaluated in a pheochromocytoma animal model. We aimed to evaluate the therapeutic effects of α-emitter 211At-MABG on a pheochromocytoma model. Methods: We evaluated tumor volume-reduction effects of 211At-MABG using rat pheochromocytoma cell line PC12 tumor-bearing mice. PC12 tumor-bearing mice received 211At-MABG (0.28, 0.56, 1.11, 1.85, 3.70 and 5.55 MBq; n = 5 each group) intravenously. The tumor volume was evaluated until 8 weeks after 211At-MABG administration. Control group (n = 10) received phosphate buffered saline (PBS). Results: The single 211At-MABG therapy showed significantly lower relative tumor growth until 38 days compared to control [relative tumor volume, control: 509.2% ± 169.1% vs. 9.6% ± 5.5% (0.56 MBq) at day 21, p < 0.01]. In addition, the 211At-MABG treatment groups with 0.28, 0.56 and 1.11 MBq showed only temporary weight reduction, recovering weight loss at day 10. Conclusion: 211At-MABG exhibited a strong tumor volume-reduction effect in a pheochromocytoma mouse model without weight reduction. Therefore, 211At-MABG might be an effective therapeutic agent for the treatment of malignant pheochromocytoma. |
|||||
| 書誌情報 |
European Journal of Nuclear Medicine and Molecular Imaging 巻 45, 号 6, p. 999-1010, 発行日 2018-01 |
|||||
| 出版者 | ||||||
| 出版者 | Springer International Publishing AG | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1619-7070 | |||||
| PubMed番号 | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 29350258 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1007/s00259-017-3919-6 | |||||
